a new formulation of graphene oxide/fluconazole compound as a promising agent against candida albicans

Candida albicans (c. albicans) belongs to the opportunistic fungal pathogens, which cause a wide spectrum of infections in immune-compromised patients. graphene oxide (go), a biocompatibility agent, has been reported to exhibit effective antimicrobial activity. in the present study, a graphene oxide/fluconazole (go/flu) compound was synthesized and characterized using fourier transform infrared spectroscopy (ftir) and raman spectroscopy. the antifungal activity of go/flu was examined against fluconazole-resistant c. albicans (atcc 10231) compared to go and flu using the broth microdilution method, according to clsi protocol. dna fragmentation was assessed through the antifungal mechanism of go/flu. the release of fluin pbs medium was measured. moreover, the cytotoxicity effect of go/flu on sw480 cell line was evaluated. indeed, adhesion ability of c. albicans-treated go/flu against sw480 cell line was assessed. the minimum inhibitory concentration (mic) of go, flu, and go/flu was determined at 800 µg/ml, 16 µg/ml, and 400–9 µg/ml, respectively. notably, go/flu exhibited an intense antifungal activity compared to go and flu. in addition, go/flu showed much less cell toxicity against sw480 cell line than go and flu (p < 0.05). the release determination of flu in pbs (ph 7.4) medium was 72.42%. go/flu reduced the adhesion ability of c. albicans to sw480 cell line significantly. dna fragmentation assay indicated that go/flu potentially degraded the dna of c. albicans and caused a fungicidal influence. according to the findings, go/flu could enhance the antifungal activity against c.albicans through dna fragmentation with low cytotoxicity effect.